
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Medicinal Chemicals & Botanical Products · market cap $109M
Research and calibrated estimates, not financial advice — verify before acting.
No upcoming catalysts in our calendar.
| Asset | Phase | Indication |
|---|---|---|
| ASN-002 | Phase 2 | Basal Cell Carcinoma |
| Afimoxifene (0.057%) in hydroalcoholic gel | Phase 2 | Cyclic Breast Pain, Cyclic Mastalgia |
| Dihydrotestosterone (0.7%) in hydroalcoholic gel | Phase 2 | Hypogonadism |
| 5-FU | Phase 2 | Basal Cell Nevus Syndrome |
Daily closes through 2026-03-24. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
See ProApproval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.